Please Wait.....
Report
China Nuclear Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-02-09 I 110 Pages I Mordor Intelligence
China Nuclear Imaging Market Analysis
China nuclear imaging market size in 2026 is estimated at USD 598.2 million, growing from 2025 value of USD 547.71 million with 2031 projections showing USD 929.51 million, growing at 9.22% CAGR over 2026-2031. This expansion mirrors China's drive to modernize healthcare under the Healthy China 2030 blueprint, rising public expenditure, and the widening adoption of advanced diagnostic technologies. Growing installations of PET/CT scanners, accelerating domestic radioisotope production, and regulatory reforms that prioritize innovative medical devices are strengthening the demand outlook across hospital and outpatient settings. Capital investment commitments from both central and provincial authorities, coupled with surging commercial health-insurance penetration, are improving funding pathways for high-value imaging equipment. Meanwhile, the push toward full-body PET technology-highlighted by the uEXPLORER platform-illustrates China's aspiration to lead in molecular imaging research and clinical application. However, equipment cost, isotope logistics, and a shortage of trained nuclear-medicine technologists remain structural obstacles that could temper near-term adoption trajectories.
China Nuclear Imaging Market Trends and Insights
Rising Prevalence of Cancer & CVD
China recorded 3.2 million new cancer cases in 2024, while cardiovascular disease stayed the top mortality driver, intensifying demand for high-accuracy imaging modalities. 18F-FAPI-04 PET/CT outperformed conventional 18F-FDG in pancreatic adenocarcinoma by upgrading TNM staging in 23% of evaluated patients, reinforcing the clinical case for advanced radiopharmaceuticals. Full-body PET systems uncovered lesions outside conventional fields in 8.47% of prostate-cancer patients, prompting treatment-plan revisions and signaling measurable clinical utility gains. Collectively, the oncology burden and rising lifestyle-related CVD prevalence make nuclear imaging indispensable for precision medicine strategies throughout tertiary hospitals and emerging outpatient centers.
Government Investment & Healthy China 2030 Policies
Healthy China 2030 positions nuclear medicine as a core pillar of nationwide diagnostic modernization, complemented by the Mid- and Long-Term Development Plan for Medical Isotopes (2021-2035) that earmarks funds for domestic isotope capacity. Government health-expenditure share in total spending rose from 17.1% in the early 2000s to nearly 30% by 2024, and macro projections suggest continuing uplift toward 2030. March 2025 State Council opinions introduced accelerated pathways for urgently needed medical devices, removing procedural frictions that historically delayed PET/CT approvals. Regional funding gaps persist, but targeted subsidies for western provinces plus Belt-and-Road export programs are tilting capital toward underserved markets.
High Capital Cost & Reimbursement Gaps
PET/CT scanners typically exceed USD 2 million per unit, posing financing barriers for smaller hospitals despite rising government expenditure. Supply-side subsidies narrow the gap in affluent coastal regions, whereas demand-side vouchers are more effective in less-developed provinces. Commercial insurance penetration accelerates access, yet reimbursement schedules for advanced tracers remain inconsistent across provinces. Total-body PET deployments highlighted higher false-positive rates, adding workflow complexity and imposing additional training and quality-control costs that smaller institutions struggle to absorb.
Other drivers and restraints analyzed in the detailed report include:
Aging Population & Higher Healthcare SpendDomestic Radioisotope Capacity ExpansionTalent Shortage of Nuclear-Medicine Technologists
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Equipment retained a dominant 64.12% share of the China nuclear imaging market size in 2025 as hospitals accelerated PET/CT deployment, with installed bases expected to top 1,600 units by 2025. United Imaging Healthcare's uMR Jupiter 5.0T and the NeuroEXPLORER brain PET platform underline domestic manufacturers' move into ultra-high-field and sub-millimeter imaging niches. Competitive pricing, localized service networks, and regulatory fast-tracks under NMPA guidelines sustain equipment-segment momentum across tertiary facilities.
Radioisotopes posted the fastest 9.84% CAGR, underpinned by policy-backed self-sufficiency drives and China Isotope & Radiation Corporation's 70% grip on radioactive-drug supply. SPECT tracers such as 99mTc dominate volume, while premium-priced PET isotopes-including 18F and 68Ga-lift value growth. Accelerator production cuts waste and supports decentralization, reinforcing penetration into tier-2 oncology clinics.
The China Nuclear Imaging Market Report is Segmented by Product (equipment; Radioisotope-SPECT: Technetium-99m, Thallium-201, Gallium, Iodine, Other SPECT Radioisotopes; PET: Fluorine-18, Rubidium-82, Other PET Radioisotopes), Application (cardiology, Neurology, Thyroid, Oncology, Other Applications), End User (hospitals, Diagnostic Imaging Centres, Academic & Research Institutes), and Geography.
List of Companies Covered in this Report:
GEHealthcare Siemens Healthineers Koninklijke Philips Canon United Imaging Healthcare Neusoft Medical Systems Mindray Bio-Medical Electronics Shenzhen Anke High-Tech Bruker Spectrum Dynamics Medical Positron China Isotope & Radiation Corp. Jiangsu Atom High Tech China National Nuclear Corp. Eckert & Ziegler Strahlen Curium Pharma Advanced Accelerator Applications SOFIE Biosciences Jubilant Group Shanghai YZ Radiopharma
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising prevalence of cancer & CVD
4.2.2 Government investment & Healthy China 2030 policies
4.2.3 Aging population & higher healthcare spend
4.2.4 Domestic radioisotope capacity expansion
4.2.5 AI-powered quantitative PET/CT adoption in tier-3 hospitals
4.2.6 Belt-&-Road radiopharma export incentives
4.3 Market Restraints
4.3.1 High capital cost & reimbursement gaps
4.3.2 Short half-life isotope logistics challenges
4.3.3 GMP approval bottlenecks for new cyclotrons
4.3.4 Talent shortage of nuclear-medicine technologists
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Industry Rivalry
5 Market Size & Growth Forecasts (Value, USD Million)
5.1 By Product
5.1.1 Equipment
5.1.2 Radioisotope
5.1.2.1 SPECT Radioisotopes
5.1.2.1.1 Technetium-99m (TC-99m)
5.1.2.1.2 Thallium-201 (TI-201)
5.1.2.1.3 Gallium (Ga-67)
5.1.2.1.4 Iodine (I-123)
5.1.2.1.5 Other SPECT Radioisotopes
5.1.2.2 PET Radioisotopes
5.1.2.2.1 Fluorine-18 (F-18)
5.1.2.2.2 Rubidium-82 (RB-82)
5.1.2.2.3 Other PET Radioisotopes
5.2 By Application
5.2.1 Cardiology
5.2.2 Neurology
5.2.3 Thyroid
5.2.4 Oncology
5.2.5 Other Applications
5.3 By End User (Value)
5.3.1 Hospitals
5.3.2 Diagnostic Imaging Centres
5.3.3 Academic & Research Institutes
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 GE Healthcare
6.3.2 Siemens Healthineers
6.3.3 Philips Healthcare
6.3.4 Canon Medical Systems
6.3.5 United Imaging Healthcare
6.3.6 Neusoft Medical Systems
6.3.7 Mindray Bio-Medical Electronics
6.3.8 Shenzhen Anke High-Tech
6.3.9 Bruker Corporation
6.3.10 Spectrum Dynamics Medical
6.3.11 Positron Corporation
6.3.12 China Isotope & Radiation Corp.
6.3.13 Jiangsu Atom High Tech
6.3.14 China National Nuclear Corp.
6.3.15 Eckert & Ziegler Strahlen
6.3.16 Curium Pharma
6.3.17 Advanced Accelerator Applications
6.3.18 SOFIE Biosciences
6.3.19 Jubilant Pharma
6.3.20 Shanghai YZ Radiopharma
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security